The urgent need for a TB vaccine

A vaccine is necessary to end the TB epidemic. IAVI and partners continue to make strides to reach this goal.

The world’s biggest infectious killer

Tuberculosis (TB), declared a public health emergency by the World Health Organization (WHO) in 1993, remains a major global health threat. TB kills more people than any other single infectious disease, and today, 4,000 die of TB every day. TB is one of the major contributors to the global burden of antimicrobial resistance, with multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) both on the rise. TB is primarily a disease of poverty, with over 90% of TB cases occurring in developing and emerging economies and imposing an enormous socio-economic burden on patients, families, and communities. It has become clear that we are far off course to reach the WHO goal to end TB by 2035. This cannot be achieved without new vaccines, diagnostics, and drugs.

Limited impact of existing vaccine

There is only one TB vaccine, bacillus Calmette-Guérin (BCG), which is nearly 100 years old. The vaccine has efficacy in protection against severe tuberculosis disease, such as TB meningitis and miliary TB, in infants and young children, but offers variable and mostly poor protection against lung disease in adolescents and adults. The latter populations are responsible for spreading TB in the community. To interrupt transmission, new and more effective vaccines that target adolescents and adults are therefore needed.

Reaching the WHO End TB Strategy targets of a 95% reduction in TB mortality and a 90% reduction in TB incidence, worldwide, by 2035, will require a new vaccine that is effective at preventing adult tuberculosis.

<table>
<thead>
<tr>
<th>TB by Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.0 million people developed TB disease in 2019</td>
</tr>
<tr>
<td>1.4 million people died of TB disease in 2019</td>
</tr>
<tr>
<td>25% of people globally may be infected with TB</td>
</tr>
<tr>
<td>$1.3 billion funding gap for TB</td>
</tr>
<tr>
<td>820,000 new TB cases among people living with HIV in 2019</td>
</tr>
</tbody>
</table>

Sources available at iavi.org/fact-sheets-sources

TB R&D shortfall

TB R&D has been chronically underfunded in relation to the impact of TB upon global health, even though it causes more deaths than HIV/AIDS and malaria combined. The Declaration of the 2018 UN High-Level Meeting on Ending TB included the Stop TB Partnership’s call for TB R&D investment to be increased to meet the funding shortfall of $1.3 billion, whilst also noting the importance of developing new and effective vaccines. Meanwhile, the WHO has concluded that ‘targets for 2035 cannot be met without intensified R&D.’
TB vaccine development is at a critical juncture

We are just now making breakthroughs in clinical efficacy trials, animal models, and new candidates that will inform the next generation of research and clinical development. If these advances are slowed, the world is likely to lose 10-20 years of progress toward a successful vaccine. We now need to accelerate the development of TB vaccines: we need to confirm the results of the recent studies, test TB vaccines in broader populations, plan for licensure trials, and develop roadmaps to ensure prompt and equitable access to future TB vaccines.

New TB vaccines on the horizon

Recent significant trial results suggest new effective TB vaccines can be developed in the coming decade if appropriate investments are made. Moreover, there are ongoing efforts across the TB research community to broaden the diversity of immune responses through innovative and emerging platforms, such as nucleic acid vector approaches, antibody mediated protection, and improved protein adjuvant combinations. Funders must invest in all phases of research and develop a plan for access to bring the first of a new generation of safe and effective TB vaccines to the people who need them most.

The impact of COVID-19 on TB

Modelling from STOP TB Partnership finds that the COVID-19 pandemic could result in a setback of at least five to eight years in the fight against TB, with an additional 6.3 million people falling ill with TB and an additional 1.4 million TB deaths over the next five years, including an up to an additional 400,000 deaths in 2020 alone.

Why do we need a vaccine to end the TB epidemic?

- Vaccines typically provide long-lasting protection.
- Vaccines could eliminate adherence and stigma problems associated with TB treatment.
- Vaccines would reduce the incidence of MDR- and XDR-TB.
- Vaccines would prevent TB transmission, having a significant impact on the epidemic.

Global TB Vaccine Pipeline

<table>
<thead>
<tr>
<th>Overall pipeline</th>
</tr>
</thead>
<tbody>
<tr>
<td>15+ trials whole-cell, subunit, and viral-vector candidates in all phases</td>
</tr>
</tbody>
</table>

Late-phase Efficacy Trials

| 7 trials whole-cell and subunit in phase 2 proof-of-concept to Phase III |

IAVI Clinical Trial Collaborations

| 3 trials whole-cell and subunit in Phases II and III |

IAVI gratefully acknowledges the generous support provided by the following major donors:

Foundation for the National Institutes of Health | National Institute of Allergy and Infectious Diseases | amfAR, The Foundation for AIDS Research | The Burners Group | Broadway Cares/Equity Fights AIDS | Cancer Research UK | The City of New York, Economic Development Corporation | Congressionally Directed Medical Research Program (DoD) | GSK | The Hearst Foundations | Keith Haring Foundation | Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the USA and Canada)

And many other generous individuals and partners around the world

As of September 2020

iavi.org
info@iavi.org

Go to iavi.org/subscribe to receive our updates
Find us on Twitter @iavi